Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia.
The WHO classification of hematological malignancies includes 5q-syndrome as a separate category within myelodysplastic syndromes (MDS). Clinically, patients with 5q-syndrome have a milder disease than patients with other MDS. The basis for this difference is not known. Identifying 5q-syndrome can be difficult because some of its morphologic and cytogenetic features are similar to those of other MDS. We compared apoptosis between 5q-syndrome and other refractory anemias. We found lower levels of apoptosis in 5q-syndrome as detected by less disruption of mitochondrial potential (P=0.008) and decreased annexin V positivity (P=0.01). Our results suggest that lower apoptosis in 5q-syndrome may explain the milder clinical course of the disease and distinguish 5q-syndrome from other MDS.
Washington
LaBaron T
LT
Department of Hematopathology, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 72, Houston, TX 77030-4095, USA.
Jilani
Iman
I
Estey
Eli
E
Albitar
Maher
M
D000753:Anemia, Refractory / Q000235:genetics / Q000503:physiopathology*; D017304:Annexin A5 / Q000378:metabolism; D017209:Apoptosis / Q000235:genetics*; D001853:Bone Marrow / Q000473:pathology; D025063:Chromosome Disorders / Q000235:genetics*; D002895:Chromosomes, Human, Pair 5; D003937:Diagnosis, Differential; D017353:Gene Deletion; D006801:Humans; D007425:Intracellular Membranes / Q000502:physiology; D008564:Membrane Potentials; D008928:Mitochondria / Q000502:physiology / Q000648:ultrastructure; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000235:genetics / Q000503:physiopathology*; D011379:Prognosis; D013577:Syndrome
D017304:Annexin A5